Finasteride for hair loss: what the controlled trials show

Male pattern hair loss, or androgenetic alopecia, is the most common cause of thinning hair in men. Oral finasteride is one of two drugs the U.S. Food and Drug Administration has approved to treat it. This article reports what controlled trials, systematic reviews, the FDA label, and dermatology sources show, both where the evidence is strong and where it is contested.

How finasteride works

Finasteride blocks the type II 5-alpha-reductase enzyme, which converts testosterone into dihydrotestosterone (DHT). DHT is the hormone that shrinks scalp hair follicles in genetically susceptible men. At the 1 mg daily dose used for hair loss, finasteride lowers scalp and blood DHT, which is the mechanism behind both its benefits and its potential side effects (FDA prescribing information).

What the efficacy trials found

The pivotal evidence comes from two 1-year randomized, double-blind, placebo-controlled trials in 1,553 men aged 18 to 41, with most continuing into a blinded second year (Kaufman et al., JAAD, 1998). Hair was counted in a fixed 1-inch circle of balding vertex scalp, starting from a baseline of about 876 hairs. Men on finasteride gained about 107 hairs above baseline at one year and 138 at two years compared with placebo, while the placebo groups kept losing hair over the same period. The core finding is twofold: finasteride slowed progression, and it produced a measurable regrowth on average.

Blinded expert panels also rated standardized photographs. In these assessments, 48% of finasteride-treated men were rated improved at one year and 66% at two years, versus 7% of placebo-treated men (FDA prescribing information). Counting men who improved plus those who held steady, the large majority avoided visible worsening, whereas most placebo users declined. A separate five-year analysis reported that hair-count gains were broadly maintained over time, and a long-term study found finasteride reduced the likelihood of further visible loss (Finasteride Male Pattern Hair Loss Study Group, 2002; 2008). The benefit depends on continued use, and stopping leads to loss of the gained hair over the following months.

The safety record in the trials

In the year-one controlled trials, drug-related sexual side effects were uncommon and each fell below 2%: decreased libido in 1.8% of finasteride users versus 1.3% on placebo, erectile dysfunction in 1.3% versus 0.7%, and ejaculation disorder in 1.2% versus 0.7% (FDA prescribing information). The label states that these effects resolved in men who discontinued the drug and in most men who continued it, and that reported rates declined further over five years of use.

Pooled analysis puts the signal in perspective. A meta-analysis of 15 randomized, double-blind, placebo-controlled trials covering 4,495 subjects found a 1.57-fold relative risk of sexual dysfunction with 5-alpha-reductase inhibitors, higher for finasteride (1.66) than dutasteride (1.37) (Acta Dermato-Venereologica, 2019). Because the absolute rates are low, a modest relative increase still translates into a small share of users. Researchers have also flagged a nocebo effect, where being warned about sexual risks appears to raise the rate of reported symptoms, which complicates interpretation of both trial and real-world data.

Real-world reports and the post-finasteride syndrome debate

Beyond the trials sits a contested question: do some men develop symptoms that persist after they stop the drug? The FDA label was updated to note post-marketing reports of sexual dysfunction that continued after discontinuation, including erectile, libido, ejaculation, and orgasm disorders, along with reports of depression and suicidal ideation, and of male infertility or poor semen quality that often improved after stopping (FDA prescribing information).

A cluster of these persistent complaints has been labeled post-finasteride syndrome. Review articles acknowledge that a body of observational, pharmacovigilance, and survey evidence documents these reports, and that some patients clearly experience lasting symptoms (Fertility and Sterility, 2020). At the same time, the same reviews stress the limits: there is no standardized diagnostic definition, the underlying data are largely retrospective and uncontrolled, causality is not established, and there is no evidence-based treatment. The reporting is therefore genuine, but the mechanism, frequency, and even the status of the syndrome as a distinct entity remain unresolved in the literature.

Dutasteride, more potent and used off-label

Dutasteride blocks both type I and type II 5-alpha-reductase and suppresses DHT more strongly than finasteride. It is approved for enlarged prostate, not hair loss, so its use for androgenetic alopecia is off-label. A randomized, placebo- and finasteride-controlled trial found dutasteride 0.5 mg daily was the most effective dose for hair count (Gubelin Harcha et al., JAAD, 2014), and a systematic review and meta-analysis reported dutasteride produced a larger mean hair-count gain than finasteride, a difference of about 28.6 hairs (Clinical Interventions in Aging, 2019). Sexual side-effect rates in these comparisons were broadly similar between the two drugs, so the trade-off is greater potency against a longer half-life and off-label status.

Topical finasteride

Applying finasteride to the scalp aims to keep the follicle-level benefit while limiting whole-body exposure. In a phase 3 randomized trial, topical finasteride raised target-area hair count more than placebo (a gain of 20.2 versus 6.7 hairs at 24 weeks), and it reduced blood DHT far less than the oral form (a 34.5% fall versus 55.6% with oral finasteride) (Piraccini et al., JEADV, 2022). Meta-analysis of topical trials found no statistically significant increase in erectile dysfunction or reduced libido versus placebo, though these studies are shorter and smaller than the oral evidence base.

Not appropriate for people who can become pregnant

Because finasteride lowers DHT, which is needed for normal development of the external genitalia of a male fetus, it is contraindicated in people who are or may become pregnant (FDA prescribing information). The label also warns that pregnant people should not handle crushed or broken tablets because of possible absorption.

This is evidence reporting, not medical advice. Individual risks and benefits vary, and decisions about any medication should be made with a qualified clinician.

Common questions

How well does oral finasteride work in the trials?

In two-year randomized trials, finasteride 1 mg increased vertex hair counts while placebo groups kept losing hair, and blinded photo panels rated 66% of treated men as improved at two years versus 7% on placebo. Counting improvement plus stabilization, most men avoided visible worsening. The benefit requires continued use and reverses within months of stopping.

How common are sexual side effects with finasteride?

In the year-one controlled trials, each of decreased libido, erectile dysfunction, and ejaculation problems was reported by under 2% of users, roughly one percentage point above placebo. The FDA label states these resolved in men who stopped and in most who continued. Pooled trial data show a modest 1.57-fold relative risk of sexual dysfunction.

Is post-finasteride syndrome real?

Reports of symptoms persisting after stopping the drug are documented in post-marketing surveillance and observational studies, and the FDA label notes them. Reviewers acknowledge that some men experience lasting symptoms, but also stress that there is no standardized diagnostic definition, the data are largely uncontrolled, causality is unproven, and no evidence-based treatment exists.

Is dutasteride better than finasteride for hair loss?

Dutasteride suppresses DHT more strongly and produced larger hair-count gains than finasteride in head-to-head trials and meta-analysis, with broadly similar sexual side-effect rates. It is approved for prostate enlargement, not hair loss, so its use for androgenetic alopecia is off-label.

Does topical finasteride reduce side effects?

Trials show topical finasteride improves hair count while reducing blood DHT much less than the oral form, and meta-analysis found no statistically significant rise in erectile dysfunction or reduced libido versus placebo. These studies are shorter and smaller than the decades of oral evidence, so long-term safety is less established.